Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes

• Published in: Nutrition & diabetes Vol. 12; no. 1; pp. 35 - 13
• Main Authors: Vanweert, Froukje, Schrauwen, Patrick, Phielix, Esther
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 05.08.2022; Nature Publishing Group
• Subjects: 692/699/2743/137/773; 692/699/2743/393; Clinical Nutrition; Diabetes; Epidemiology; Homeostasis; Insulin resistance; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Metabolism; Obesity; Pathogenesis; Review; Review Article
• ISSN: 2044-4052; 2044-4052
• DOI: 10.1038/s41387-022-00213-3

Branched-chain amino acid (BCAA) catabolism has been considered to have an emerging role in the pathogenesis of metabolic disturbances in obesity and type 2 diabetes (T2D). Several studies showed elevated plasma BCAA levels in humans with insulin resistance and patients with T2D, although the underlying reason is unknown. Dysfunctional BCAA catabolism could theoretically be an underlying factor. In vitro and animal work collectively show that modulation of the BCAA catabolic pathway alters key metabolic processes affecting glucose homeostasis, although an integrated understanding of tissue-specific BCAA catabolism remains largely unknown, especially in humans. Proof-of-concept studies in rodents -and to a lesser extent in humans – strongly suggest that enhancing BCAA catabolism improves glucose homeostasis in metabolic disorders, such as obesity and T2D. In this review, we discuss several hypothesized mechanistic links between BCAA catabolism and insulin resistance and overview current available tools to modulate BCAA catabolism in vivo. Furthermore, this review considers whether enhancing BCAA catabolism forms a potential future treatment strategy to promote metabolic health in insulin resistance and T2D.